5/4/2018. Disclosures. PsA: A heterogeneous disease. Objectives. PsA: A heterogeneous disease Fatigue
|
|
- Warren Perkins
- 6 years ago
- Views:
Transcription
1 5//18 Disclosures Management of Psoriatic Arthritis Alexis Ogdie, MD MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Psoriatic Arthritis Clinic Division of Rheumatology Center for Clinical Epidemiology and Biostatistics Perelman School of Medicine University of Pennsylvania Consulting: Amgen, Abbvie, BMS, Celgene, Lilly, Novartis, Pfizer, Takeda Grants: NIH/NIAMS, RRF, Novartis, Pfizer I am a member of the ACR/NPF treatment guidelines team what I say today is separate from that project and doesn t reflect that work. Objectives PsA: A heterogeneous disease Consider the broader context of disease in management of PsA Discuss treatment strategies Examine available therapies for PsA, their mechanisms of action, and potential benefits and risks PsA: A heterogeneous disease Fatigue Work Productivity Social Participation Less than 3% of patients with PsA reach remission by any definition Physical Function and Disability Family Role Emotional Wellbeing Poor Sleep Orbai et al. Ann Rheum Dis 17 Michelson et al, J Rheumatol 17 1
2 5//18 Treating PsA = Treating the Whole Patient Physical therapy Sleep physician or Sleep psychologist Exercise and muscle balance Sleep Fatigue Nutritionist Diet MSK Emotional wellbeing Dermatologist Skin and Nail Family and Friends Specialty Pharmacist Treatment Burden Work Concomitant Conditions Primary Care Screening for CVD, Diabetes, osteoporosis, IBD, Uveitis, Skin Cancer, etc Therapy, Psychiatry, Occupational therapy What do you need to know before choosing a therapy? manifestations Concomitant Conditions Extraarticular manifestations and comorbidities Prior therapies Primary failure vs secondary failure Patient preferences The target Peripheral Arthritis Axial Enthesitis Dactylitis Skin Nail PsA is associated with several concomitant conditions, particularly metabolic disease GRAPPA Guidelines (15) Inflammatory Bowel Cardiovascular Eye PsA Obesity Diabetes Coates et al, Arthritis Rheum 1 Depression and Anxiety Fatty Liver Ogdie A, et al. Curr Opin Rheumatol. 15 Treat to Target Follow up on change Select Target Modify treatment to get to target Objectively Monitor Primary target: Remission Alternative target: LDA Coates et al. Lancet 1 Smolen et al. Ann Rheum Dis 17 Treatment Targets in PsA Minimal Activity (MDA) defined as 5/7 of the following: Tender joint count 1 Swollen joint count 1 PASI 1 or BSA 3 Patient pain VAS 15 Patient global activity VAS HAQ.5 Tender entheseal points 1 activity in PsA (DAPSA): Tender joint count + Swollen joint count + Patient pain (11) + Patient global activity (11) + CRP Coates et al. Lancet 1 Smolen et al. Ann Rheum Dis 17 Coates & Helliwell. Curr Rheum Reports 15 Coates et al. Arthritis Rheum 17
3 5//18 The Tight Control in Psoriatic Arthritis (TiCOPA) trial ACR Tight Control PASI75 Standard Therapies for PsA However, must balance increased adverse events with better efficacy Coates et al. Lancet 1 Overview of disease pathophysiology Microbiome HLAB7 Biomechanical Stress/Trauma Infection Lories, R. Nature Med. 1; 18(7):118 SpA Treatment Toolbox NSAIDs Glucocorticoids Oral Small Molecules Methotrexate Leflunomide Sulfasalazine Cyclosporine TNF alpha inhibitors Etanercept Adalimumab Infliximab Certulizimab Golimumab Local Glucocorticoid Injections New MOA therapies Ustekinimab (IL1/3i) Apremilast (PDEi) Secukinumab (IL17i) Abatacept (CTLA Ig) Ixekizumab (IL17i) Tofacitinb (JAK3) In Development/Not Approved Brodalumab (IL17R) Guselkumab (IL3i) Tildrakizumab (IL3i) Rizankizumab (IL3i) =option for spondylitis Adjunct Therapy *Limited evidence Physical therapy Occupational therapy Exercise Weight Loss Dietary Changes? Acupuncture Omega3FA Patient Education Social Support Talk Therapy PsA: A heterogenous disease But most clinical trial outcomes are focused on the joints.... Clinical Trial Outcomes in PsA ACR % improvement in tender and swollen joint counts plus % in at least three of the following Health Assessment Questionnaire Patient pain assessment Patient global assessment Physician global assessment Acute Phase Response: Creactive protein PASI75 75% improvement in PASI (Psoriasis Area and Severity Index) score (range 7) Head, Trunk, Arms, Legs %BSA in each area, Erythema, Induration, Desquamation Weighted score 3
4 Hazard ratios 5//18 Overall limited data for the oral small molecules ( traditional DMARDs ) Methotrexate in PsA (MIPA) Trial Target dose of methotrexate = 15 mg weekly MTX Placebo In clinical practice, they do help Inexpensive Around for a long time Really a lack of data; not many studies and studies use relatively low doses However, TiCOPA may suggest that we re just not aggressive enough? Existing data does not support a disease modifying effect MTX helps psoriasis but not SSA; LEF a little but not much A major role may be in suppressing antibody formation and prolonging the life of the biologic OR (95%CI) pvalue PsARC 1.77 (.973.3). ACR. (.5.).3 DAS8 Response 1.7 (.93.17).1 PASI Swollen Joints MTX Placebo Tender Joints Physician Global MTX Placebo Patient Global Baseline Follow up 3 Months Kingsley et al. Rheumatology 1; 51: Liver disease Mild psoriasis Severe psoriasis PsA, no DMARD PsA, DMARD RA, no DMARD Any liver disease Cirrhosis NAFLD RA, DMARD Ogdie A, et al. J Invest Derm. 18 TNF inhibitors Human variable region Human IgG1 Fc Adalimumab & Golimumab Fully human monoclonal antitnf antibodies Extracellular domain of human TNFR Human IgG1 Fc Etanercept Fusion protein Mouse variable region Infliximab Chimeric human (75%)/mouse (5%) monoclonal antitnf antibody Humanized variable region Certolizumab pegol PEGylated Fab 1 fragment Human IgG1 Fc PEG Differentiating Among TNFi: Uveitis/Crohn s/uc Severity of Psoriasis Mode (IV vs SQ) Dosing Intervals Insurance Coverage To use combination therapy or not? Mantravadi et al. Expert Rev Clin Pharmacol 17 Apremilast, a phosphodiesterase inhibitor Ustekinumab: p subunit, IL1/3 inhibitor PDE PDE p p35 p p19 Degradation of camp PKA Accumulation of camp PKA NF B CREB Increases inflammatory cytokines: TNF, IFNɣ, IL1, IL3, IL17, IL ATF1 NF B ATF1 IL1 receptor IL3 receptor CREB Decreases inflammatory cytokines: TNF, IFNɣ, IL1, IL3, IL17, IL T H 1 cell signaling T H 17 cell signaling
5 5//18 Secukinumab (IL17Ai) IL17 inhibitors Ixekizumab (IL17Ai) Tofacitinib AntiIL17 AntiIL17 IL17 A IL17F IL17A/ IL17F IL17RA IL17RC IL17RA IL17RC IL17RA IL17RC AntiIL17RA Brodalumab (IL17RAi) Winthrop. Nature Rev Rheum 17 Abatacept Drugs in Development Brodalumab (approved for psoriasis) Guselkumab (approved for psoriasis) Tildrakizumab (approved for psoriasis) Rizankizumab (Phase II in PsA complete, Phase III in PsO complete) Upadacitinib (phase II) Ruderman and Pope Nat Rev Review IL3 Inhibition p p35 IL1 receptor T H 1 cell signaling p p19 IL3 receptor T H 17 cell signaling Guselkumab Phase II for PsA (approved for psoriasis in 17) ACR PASI75 GUS Placebo Deodhar et al. ACR Annual Meeting Abstract L VOYAGE I Trial: Blauvelt et al. JAAD 17 5
6 5//18 Conclusions Key considerations in therapy selection: Level of disease activity: skin and MSK severity manifestations Comorbidities Patient preference Treat to Target Broader concept than using MDA just use SOMETHING! Many new therapies in PsA and more therapies to come! One prescription isn t going to solve all of the problems Consider the broader context and impact of the patient s disease in designing a management plan. Acknowledgements Collaborators Kat Bush and Santhi Mantravadi PARC Team: Jose Scher, MD, Souyma Reddy, MD, Elaine Husni, MD MPH, Jessica Walsh, MD MBA Penn Collaborators: Joel Gelfand, MD MSCE, Andrea Troxel, ScD, Alisa StephensShields, PhD, Joshua Baker, MD MSCE OMERACT: AnaMaria Orbai, MD, Laura Coates, MD, Dafna Gladman, MD, Vibeke Strand, MD, Philip Mease, MD Corrona Investigators: Lynn Palmer, PhD Jeff Curtis, MD, MS, MPH, Arthur Kavanaugh, MD, Dan Solomon, MD, MPH, Philip Mease, MD, Joel Kremer, MD, Jeff Greenberg MD Funding
Psoriatic Arthritis: New and Emergent Therapies
Psoriatic Arthritis: New and Emergent Therapies Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS
More informationNeil McHugh Royal National Hospital for Rheumatic Diseases University of Bath
Psoriatic arthritis Neil McHugh Royal National Hospital for Rheumatic Diseases University of Bath The Spondyloarthropathies Axial Spondyloarthropathy Peripheral joint arthritis Features Spondylitis Uveitis
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationProper treatment of psoriatic arthritis (PsA) requires. Update on Treatment of Psoriatic Arthritis. Philip Mease, M.D.
167 Update on Treatment of Psoriatic Arthritis Philip Mease, M.D. Abstract Some of this past year s key papers or abstracts on psoriatic arthritis (PsA) assessment and treatment are reviewed in this paper.
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationPsoriatic arthritis (PsA) is a form of inflammatory
243 Psoriatic Arthritis Treatment Update Philip J. Mease, M.D. Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in approximately 10% to 30% of individuals with psoriasis, depending
More informationUpdate on Psoriatic Arthritis: Best Practices in Rheumatology
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationClinical Practice Guideline. Psoriatic Arthritis (PsA) Version
Clinical Practice Guideline Psoriatic Arthritis (PsA) Version 1.1.2016 August 2016 Table of Contents Introduction...5 Diagnosis...6 Patient Assessment... 7 Management of Patients with PsA...8 Peripheral
More informationHorizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716
Horizon Scanning Centre January 2013 Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716 This briefing is based on information available at the time of research and a limited literature search.
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More informationBOARD CERTIFIED IN RHEUMATOLOGY NURSING
Inside this Issue ISSUE 3 VOLUME 3»»»» Which disease states are included within the broader family of the spondyloarthopathies? How do the primary characteristics of the spondyloarthopathies differ from
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationThe New and Emerging Agents: Dermatology
Psoriasis Treatment 2013: What is New and on the Horizon? Neil J Korman, MD, PhD Professor of Dermatology University Hospitals Case Medical Center Clinical Director Murdough Family Center for Psoriasis
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationintolerance to tumour necrosis
To cite: Nash P, Behrens F, Orbai A-M, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic diseasemodifying antirheumatic drugs (cdmards) in patients with active psoriatic
More informationA Patient s Guide to. Treatments for Psoriatic Arthritis
A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this
More informationNational Doral, Miami, Florida 7:20 AM 8:20 AM, Ballroom B. Supported by an educational grant from Novartis Pharmaceuticals Corporation.
National Doral, Miami, Florida 7:20 AM 8:20 AM, Ballroom B Supported by an educational grant from Novartis Pharmaceuticals Corporation. Allan Gibofsky, MD, JD, MACR, FACP, FCLM Weill Medical College of
More informationDrug Class Update with New Drug Evaluation: Biologics for Autoimmune Conditions
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationFrom Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment
From Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment Final Enduring Outcomes Report Celgene Grant #20502 Janssen Grant #CE15843 Novartis Grant #NGC29612 Reflective of
More informationTreatment of psoria.c arthri.s: Guidelines and beyond. Pascal RICHETTE Hôpital Lariboisière, Paris
Treatment of psoria.c arthri.s: Guidelines and beyond Pascal RICHETTE Hôpital Lariboisière, Paris The pa.ent: a 37 year- old man, with a history of psoriasis for 10 years Past history: - Dyslipidemia Current
More informationAssessing Disease Activity in Psoriatic Arthritis: A Literature Review
Rheumatol Ther (2019) 6:23 32 https://doi.org/10.1007/s40744-018-0132-4 REVIEW Assessing Disease Activity in Psoriatic Arthritis: A Literature Review Laura J. Tucker. Laura C. Coates. Philip S. Helliwell
More informationDrug Class Update with New Drug Evaluation: Biologics for Autoimmune Conditions
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationWelcome and Overview. Melodie Young, MSN, ANP-C Nurse Practitioner, Modern Dermatology Partner, Modern Research Associates Dallas, Texas
Welcome and Overview Melodie Young, MSN, ANP-C Nurse Practitioner, Modern Dermatology Partner, Modern Research Associates Dallas, Texas Advances in Biologic Therapies for Psoriasis April W. Armstrong,
More informationDisclosures. Activity Information. Updates in Psoriasis Therapy. Ustekinumab Guselkumab Tildrakizumab. Secukinumab Ixekizumab Brodalumab
Disclosures Faculty: Teri Greiling, MD, PhD, has disclosed the following conflicts of interest: research funding: Eli Lilly. Updates in Psoriasis Therapy 12 October 2018 St. Charles Medical Center Teri
More informationPublic observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationResearch Developments in Psoriasis Treatment A CME Activity
Overview Research Developments in Psoriasis Treatment A CME Activity Mark Lebwohl, MD, Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, provides his perspectives
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationPsoriatic Arthritis- Second Line Treatments
Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist
More informationNEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Madrid, Spain,
More informationThis is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced.
This is a repository copy of New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/102808/
More informationPsoriasis and Psoriatic Arthritis Treatment
n REPORT n Psoriasis and Psoriatic Arthritis Treatment Alan Menter, MD Overarching Principles of Psoriasis and Psoriatic Arthritis Treatment Several best practices have emerged to guide the management
More informationGroup for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
ARTHRITIS & RHEUMATOLOGY Vol. 68, No. 5, May 2016, pp 1060 1071 DOI 10.1002/art.39573 VC 2016, American College of Rheumatology SPECIAL ARTICLE Group for Research and Assessment of Psoriasis and Psoriatic
More information3 rd Appraisal Committee meeting, 28 February 2017 Committee D
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple Technology Appraisal 3 rd Appraisal Committee
More informationRheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW POLAND prof. Małgorzata Wisłowska
Rheumatology and Internal Diseases Clinic of the Central Clinical Hospital in Warsaw 137 Woloska St. WARSAW 02-507 POLAND prof. Małgorzata Wisłowska MD, PhD 1 Klinika Chorób Wewnętrznych i Reumatologii
More informationTHE PATIENT S PERSPECTIVE ON PSORIATIC ARTHRITIS: WHAT MORE CAN RHEUMATOLOGISTS DO TO OPTIMISE DISEASE MANAGEMENT?
THE PATIENT S PERSPECTIVE ON PSORIATIC ARTHRITIS: WHAT MORE CAN RHEUMATOLOGISTS DO TO OPTIMISE DISEASE MANAGEMENT? This symposium took place on 16 th June 2017 as a part of the European League Against
More informationapremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.
apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More information1. Joining the Dots in Psoriatic Arthritis; 2. Reaching for a Cure for Hep C
Dr Daniel Ching Consultant Rheumatologist Timaru Hospital Dr Catherine Stedman Gastroenterologist Hepatologist, Christchurch Hospital, Clinical Senior Lecturer, University Otago 7:00-8:00 Abbvie Breakfast
More informationBreakthrough Drugs in Dermatology. Mark Lebwohl, MD
Breakthrough Drugs in Dermatology Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai LIFE CHANGING
More informationMEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Psoriatic Arthritis (PsA) P&T DATE 2/15/2018 CLASS:
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Psoriatic Arthritis (PsA) P&T DATE 2/15/2018 CLASS: LOB: Rheumatology/Anti-Inflammatory Disorders MCL REVIEW HISTORY 2/17,
More informationSwitching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence
Drugs R D (2017) 17:509 522 DOI 10.1007/s40268-017-0215-7 REVIEW ARTICLE Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence Luisa Costa 1 Carlo Perricone 2 Maria Sole
More informationHelliwell et al. Arthritis Research & Therapy (2018) 20:242
Helliwell et al. Arthritis Research & Therapy (2018) 20:242 https://doi.org/10.1186/s13075-018-1739-0 RESEARCH ARTICLE Open Access Disease-specific composite measures for psoriatic arthritis are highly
More informationBiologics and Psoriasis: The Beat Goes On
Biologics and Psoriasis: The Beat Goes On Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationADDITIONAL RESOURCES. Friday, September 14, Encore at Wynn Las Vegas, Nevada TABLE OF CONTENTS
ADDITIONAL RESOURCES Friday, September 14, 2018 Encore at Wynn Las Vegas, Nevada TABLE OF CONTENTS Faculty Bios... 2 Pretest/Posttest Explanations... 3-7 Key References... 8-9 Generic Trade Name Identification
More informationSIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Commercial Medical Benefit Drug Policy SIMPONI ARIA (GOLIMUMAB) INJECTION FOR INTRAVENOUS INFUSION Policy Number: PHA031 Effective Date: March 1, 2019 Table of Contents Page COVERAGE RATIONALE...
More informationCoates et al. Arthritis Research & Therapy (2018) 20:272 (Continued on next page)
Coates et al. Arthritis Research & Therapy (2018) 20:272 https://doi.org/10.1186/s13075-018-1773-y RESEARCH Open Access Secukinumab provides sustained PASDASdefined remission in psoriatic arthritis and
More informationOVERVIEW OF PSORIATIC ARTHRITIS: CLINICAL CONSIDERATIONS FOR HEALTHCARE PROFESSIONALS JAMIE L. MCCONAHA, PHARMD, NCTTP, BCACP, CDE
OVERVIEW OF PSORIATIC ARTHRITIS: CLINICAL CONSIDERATIONS FOR HEALTHCARE PROFESSIONALS JAMIE L. MCCONAHA, PHARMD, NCTTP, BCACP, CDE FACULTY DISCLOSURES I have no conflicts of interest to disclose. I do
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationPsoriatic Arthritis- Secondary Care
Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the
More informationPharmacy Accreditation
EASING THE PATIENT BURDEN OF PSORIASIS AND PSORIATIC ARTHRITIS: THE ROLE OF THE SPECIALTY PHARMACIST Claire Lee, PharmD, CSP, CPHQ Clinical Quality Improvement Supervisor Diplomat Flint, Michigan Pharmacy
More informationcertolizumab pegol (Cimzia )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationA. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria)
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 7 July 2017 PP. 08-12 Vascular endothelial growth factor (VEGF), cartilage oligomeric
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More informationMethotrexate in Psoriatic Arthritis
S41 Methotrexate in Psoriatic Arthritis Philip Mease, M.D. Abstract Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in patients with psoriasis and is distinct from rheumatoid
More informationImproved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial
Strand et al. Arthritis Research & Therapy (2018) 20:269 https://doi.org/10.1186/s13075-018-1769-7 RESEARCH ARTICLE Open Access Improved patient-reported outcomes in patients with psoriatic arthritis treated
More informationTRANSPARENCY COMMITTEE OPINION. 26 April 2006
TRANSPARENCY COMMITTEE OPINION 26 April 2006 REMICADE 100 mg powder for concentrate for solution for infusion Box of 1 (CIP code: 562 070.1) Applicant : laboratoires Schering Plough List I Drug for hospital
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Secukinumab for treating ankylosing spondylitis after inadequate response to non-steroidal anti-inflammatory drugs
More informationSTELARA DATA SHEET NAME OF THE MEDICINE DESCRIPTION V L C L V H C H 1 C H 2 C H 3. Fab. F(ab)' 2. hinge
DATA SHEET NAME OF THE MEDICINE Ustekinumab (rmc). CAS Registry Number: 815610-63-0. DESCRIPTION (ustekinumab) is a human IgG1kappa monoclonal antibody with an approximate molecular weight of 148,600 daltons.
More informationSYNOPSIS. Issue Date: 17 Jan 2013
STELARA (ustekinumab) Clinical Study Report CNTO1275PSA3002 24-Week CSR SYNOPSIS Issue Date: 17 Jan 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research &
More informationArthritis: Incorporating
From Psoriasis to Psoriatic Arthritis: Incorporating Advances to Individualize Treatment Interim Outcomes Report Celgene Grant #20502 Janssen Grant #CE15843 Novartis Grant #NGC29612 Reflective of data
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationTherapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol
Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
DERBYSHIRE JOINT AREA PRERIBING COMMITTEE (JAPC) Derbyshire commissioning guidance on biologic drugs f the treatment of Rheumatoid arthritis with methotrexate This algithm is a tool to aid the implementation
More informationInternational DErmatology Outcomes Measures. Modeled after OMERACT: Outcomes Measures in Rheumatology
International DErmatology Outcomes Measures Modeled after OMERACT: Outcomes Measures in Rheumatology 1992 original intent: obtain agreement on the minimum number of outcome measures to be included in all
More informationOpinion 1 October 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2014 CIMZIA 200 mg, solution for subcutaneous injection 1 B/2 1 ml prefilled syringes with needle guard
More informationGaps in the Treatment of Psoriasis and PsA for Systemic Therapy
Gaps in the Treatment of Psoriasis and PsA for Systemic Therapy Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More information4/10/18. Faculty. Disclosures. Confronting Psoriatic Disease: Putting New Tools to Work
Confronting Psoriatic Disease: Putting New Tools to Work Faculty Brad P. Glick, DO, MPH, FAOCD Glick Skin Institute Skin and Cancer Associates Program Director Dermatology Residency Larkin Hospital - Palm
More informationDrug Class Update: Biologics for Autoimmune Conditions
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIs Methotrexate A Disease Modifying Agent In Psoriatic Arthritis?
Disclosure Statement Is Methotrexate A Disease Modifying Agent In Psoriatic Arthritis? Gabrielle H Kingsley Consultant and Reader in Rheumatology King s College London Lewisham Healthcare NHS Trust Dr
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationDrug Class Update with New Drug Evaluation: Biologics for Autoimmune Conditions
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationPsoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center
Psoriasis Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center Learning objectives Recognize the different types of psoriasis
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationTherapeutic Advances for the Management of Patients with Psoriatic Arthritis
Therapeutic Advances for the Management of Patients with Psoriatic Arthritis Alan L. Epstein, MD Clinical Professor of Medicine Univ. of Penn. School of Medicine Disclosure of Conflicts of Interest Alan
More informationEXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS
EXAMINING THE CRUCIAL COALITION BETWEEN DERMATOLOGY AND RHEUMATOLOGY IN PSORIATIC ARTHRITIS ACTIVITY 1: EARLY COLLABORATION IN THE TREATMENT OF PSA Key Slides COMMON COMORBIDITIES OF PSORIATIC DISEASE
More informationReview of the Psoriatic Arthritis working group at OMERACT 12: a report from the. GRAPPA 2014 annual meeting
Review of the Psoriatic Arthritis working group at OMERACT 12: a report from the GRAPPA 2014 annual meeting W. Tillett L. Eder N. Goel M. dewit A. Ogdie AM Orbai W. Campbell O. FitzGerald N. McHugh D.
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Ruperto N, Martini A. Current and future perspectives
More informationJ. Gelfand 1, A. Joshi 2, D. Shin 1, A. Dey 2, D. Torigian 1, D. Rader 1, M. Playford 2, M. Ahlman 2, A. Alavi 1, N. Mehta 2.
A Trial to Determine the Effect of Psoriasis Treatment (Adalimumab, Phototherapy, and placebo) on Cardiometabolic Disease: The Vascular Inflammation in Psoriasis (VIP) Trial Abstract 393 J. Gelfand 1,
More informationETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)
Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid
More informationSubject: Ixekizumab (Taltz ) Injection
09-J2000-62 Original Effective Date: 06/15/16 Reviewed: 09/12/18 Revised: 10/15/18 Subject: Ixekizumab (Taltz ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340
Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More information